Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized trial of RDEA806 in treatment-naïve HIV-1 infection
2007-005854-21Phase 2Completed
- Sponsor
- Ardea Biosciences Inc.
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RDEA806 in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1 (5 arms), sponsored by Ardea Biosciences Inc. Primary endpoint: Change from baseline in plasma HIV-1 viral load at end of treatment. Started Nov 2007; status: completed.
02
Drugs
RDEA806
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2007-005854-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005854-21.